Utah Medical Products INC: directors' dealings · United States · SEC (Form 4)

About Utah Medical Products INC

Utah Medical Products, Inc. (UTMD) is a U.S.-based medical device company listed on the NASDAQ in the United States. Headquartered in Midvale, Utah, UTMD focuses on specialized disposable and reusable devices used in critical care settings, with a business model centered on niche clinical applications rather than broad commodity volume. The company was formed as a Utah corporation in 1978 and completed a public stock offering in 1982, giving it a long operating history and a reputation built over decades in regulated healthcare markets. ([utahmed.com](https://utahmed.com/pdf/2024UTMD10K.pdf)) UTMD’s core commercial strength lies in women’s health and neonatal care, alongside blood pressure monitoring and other specialty hospital products. The company groups its revenues into four main categories: obstetrics; gynecology/electrosurgery/urology; neonatal; and blood pressure monitoring and accessories. Its portfolio includes the Filshie Clip System for female tubal ligation, neonatal products such as DISPOSA-HOOD, DELTRAN and GESCO-branded catheters and accessories, plus blood pressure monitoring kits used in hospital and NICU settings. In 2024, gynecology/electrosurgery/urology was the largest revenue category, followed by blood pressure monitoring, neonatal, and obstetrics. ([utahmed.com](https://utahmed.com/pdf/2024UTMD10K.pdf)) From a competitive standpoint, UTMD is best understood as a specialized, clinically oriented manufacturer with proprietary products, a global installed base, and a strong emphasis on quality, regulatory compliance and procedure-specific design. The company sells directly to end users and through distributors, and it also manufactures components and finished devices on a subcontract basis for other medical-device businesses. Outside the U.S., UTMD has direct or indirect commercial reach in Canada, the United Kingdom, France, Ireland, Australia and New Zealand, and management states that it has representation across major developed markets as well as many developing markets through roughly 200 distributors. That global footprint helps diversify demand, even though the business remains relatively concentrated in a limited number of product families. ([utahmed.com](https://utahmed.com/pdf/2024UTMD10K.pdf)) Recent company updates have been shaped by softer operating trends and capital returns to shareholders. In its 2025 quarterly releases, UTMD reported lower revenue versus the prior year, with the decline driven mainly by reduced OEM sales to PendoTECH. Even so, the company continued to post solid profitability, with margins remaining relatively high for the industry. In its January 29, 2026 year-end release, UTMD said it did not meet its beginning-of-year 2025 projections, but still ended the year with $85.8 million in cash, after paying $4.0 million in dividends and repurchasing 4.5% of its shares for $8.4 million. For investors, UTMD therefore looks like a defensive, cash-generative NASDAQ healthcare name with a modest growth profile, a specialized product mix, and meaningful exposure to litigation and customer-concentration risks. ([utahmed.com](https://www.utahmed.com/pr/UTMD-PR072425.pdf))